KRAS Testing: A Tool for the Implementation of Personalized Medicine

Genes and Cancer

Volumn 3, Issue 7-8, 2012, Pages 459-466

  Shackelford, Rodney E ^a   Whitling, Nicholas A ^a   McNab, Patricia ^b   Japa, Shanker ^a   Coppola, Domenico ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

KRAS mutation; KRAS testing methods; personalized medicine

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PANITUMUMAB;

ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL PRACTICE; CODON; COLORECTAL CARCINOMA; DENATURING GRADIENT GEL ELECTROPHORESIS; GENE SEQUENCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS CANCER; PERSONALIZED MEDICINE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CANCER;

EID: 84875540807     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912460547     Document Type: Article

References (53)

1. Bos JL.RAS oncogenes in human cancer: a review.Cancer Res. 1989;49:4682-9.
2. Andreyev HJ,Norman AR,Cunningham D, et al.Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.Br J Cancer. 2001;85:692-6.
3. Bos JL,Fearon ER,Hamilton SR, et al.Prevalence of ras gene mutations in human colorectal cancers.Nature. 1987;327:293-7.
4. Harvey JJ.An unidentified virus which causes the rapid production of tumors in mice.Nature. 1964;204:1104-5.
5. Chang EH,Gonda MA,Ellis RW,Scolnick EM,Lowy DR.Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses.Proc Natl Acad Sci U S A. 1982;79:4848-52.
6. Shih C,Padhy LC,Murray M,Weinberg RA.Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.Nature. 1981;290:261-4.
7. Zuber J,Tchernitsa OI,Hinzmann B, et al.A genome-wide survey of RAS transformation targets.Nat Genet. 2000;24 (2): 144-52.
8. Malumbres M,Barbacid M.RAS oncogenes: the first 30 years.Nat Rev Cancer. 2003;3:459-65.
9. Downward J.Targeting RAS signaling pathways in cancer therapy.Nat Rev Cancer. 2003;3:11-22.
10. Graziani A,Gramaglia D,dalla Zonca P,Comoglio PH.Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger.J Biol Chem. 1993;268:9165-8.
11. Hu YP,Patil SB,Panasiewicz M, et al.Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.Cancer Res. 2008;68:8004-13.
12. Rajalingam K,Schreck R,Rapp UR,Albert S.Ras oncogenes and their downstream targets.Biochim Biophys Acta. 2007;1773:1177-95.
13. Jancík S,Drábek J,Radzioch D,Hajdúch M.Clinical relevance of KRAS in human cancers.J Biomed Biotechnol. 2010;2010:150960.
14. Pretlow TP,Pretlow TG.Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?.Biochim Biophys Acta. 2005;1756:83-96.
15. McLellan EA,Owen RA,Stepniewska KA,Sheffield JP,Lemoine NR.High frequency of K-ras mutations in sporadic colorectal adenomas.Gut. 1993;34:392-6.
16. Sugio K,Kishimoto Y,Virmani AK,Hung JY,Gazdar AF.K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas.Cancer Res. 1994;54:5811-5.
17. Amado RG,Wolf M,Peeters M, et al.Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol. 2008;26:1626-34.
18. Karapetis CS,Khambata-Ford S,Jonker DJ, et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med. 2008;359:1757-65.
19. Linardou H,Dahabreh IJ,Kanaloupiti D, et al.Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.Lancet Oncol. 2008;9:962-72.
20. Massarelli E,Varella-Garcia M,Tang X, et al.KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Clin Cancer Res. 2007;13:2890-6.
21. De Roock W,Jonker DJ,Di Nicolantonio F, et al.Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.JAMA. 2010;304:1812-20.
22. National Comprehensive Cancer Network. NCCI Clinical Practice Guidelines in Oncology: non small cell lung cancer (version 2.2009) and colon cancer (version 3.2009). Available from: http://www.nccn.org/professionals/physician_gls/PDF/colon.ncl.pdf and http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
23. Gilbert MT,Haselkorn T,Bunce M, et al.The isolation of nucleic acids from fixed, paraffin-embedded tissues: which methods are useful when?.PLoS One. 2007;2:e537.
24. Williams C,Pontén F,Moberg C, et al.A high frequency of sequence alterations is due to formalin fixation of archival specimens.Am J Pathol. 1999;155:1467-71.
25. Franklin WA,Haney J,Sugita M,Bemis L,Jimeno A,Messersmith WA.KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.J Mol Diagn. 2010;12:43-50.
26. Tsiatis AC,Norris-Kirby A,Rich RG, et al.Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.J Mol Diagn. 2010;12:425-32.
27. Metzker ML.Emerging technologies in DNA sequencing.Genome Res. 2005;15:1767-6.
28. Weichert W,Schewe C,Lehmann A, et al.KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.J Mol Diagn. 2010;12:35-42.
29. Pang NK,Nga ME,Chin SY, et al.KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.Cytopathology. 2011;22:358-64.
30. Ibrahem S,Seth R,O'Sullivan B,Fadhil W,Taniere P,Ilyas M.Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.Int J Exp Pathol. 2010;91:500-5.
31. Gao J,Li YY,Sun PN,Shen L.Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.World J Gastroenterol. 2010;16:4858-64.
32. Ogino S,Kawasaki T,Brahmandam M, et al.Sensitive sequencing method for KRAS mutation detection by pyrosequencing.J Mol Diagn. 2005;7:413-21.
33. van Eijk R,van Puijenbroek M,Chhatta AR, et al.Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.J Mol Diagn. 2010;12:27-34.
34. Dufort S,Richard MJ,de Fraipont F.Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.Anal Biochem. 2009;391:166-8.
35. Packham D,Ward RL,Ap Lin V,Hawkins NJ,Hitchins MP.Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers.Diagn Mol Pathol. 2009;18:62-71.
36. Sundström M,Edlund K,Lindell M, et al.KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice.BMC Cancer. 2010;10:660.
37. Arcila M,Lau C,Nafa K,Ladanyi M.Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.J Mol Diagn. 2011;13:64-73.
38. Whitehall V,Tran K,Umapathy A, et al.A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.J Mol Diagn. 2009;11:543-52.
39. Gonzalez-Bosquet J,Calcei J,Wei JS, et al.Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers.PLoS One. 2011;6:e14522.
40. Deschoolmeester V,Boeckx C,Baay M, et al.KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.Br J Cancer. 2010;103:1627-36.
41. Er TK,Chang YS,Yeh KT,Chang TJ,Chang JG.Comparison of two different screening methods for the KRAS mutation in colorectal cancer.Clin Lab. 2010;56:175-86.
42. Half E,Bercovich D,Rozen P.Familial adenomatous polyposis.Orphanet J Rare Dis. 2009;4:22.
43. Hayes VM,Westra JL,Verlind E, et al.New comprehensive denaturing-gradient-gel-electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumours.Genes Chromosomes Cancer. 2000;29:309-14.
44. Lilleberg SL,Durocher J,Sanders C,Walters K,Culver K.High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.Ann N Y Acad Sci. 2004;1022:250-6.
45. Kriegshäuser G,Auner V,Schuster E, et al.KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assay.J Clin Pathol. 2011;64:252-6.
46. Prix L,Uciechowski P,Böckmann B,Giesing M,Schuetz AJ.Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool.Clin Chem. 2002;48:428-35.
47. Ausch C,Buxhofer-Ausch V,Oberkanins C, et al.Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.J Mol Diagn. 2009;11:508-13.
48. Fariña Sarasqueta A,Moerland E,de Bruyne H, et al.SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.J Mol Diagn. 2011;13:199-205.
49. Yen LC,Yeh YS,Chen CW, et al.Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.Clin Cancer Res. 2009;15:4508-13.
50. Huang MM,Arnheim N,Goodman MF.Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR.Nucleic Acids Res. 1992;20:4567-73.
51. Kimura H,Kasahara K,Kawaishi M, et al.Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.Clin Cancer Res. 2006;12:3915-21.
52. De Roock W,Claes B,Bernasconi D, et al.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010;11:753-62.
53. Di Nicolantonio F,Martini M,Molinari F, et al.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol. 2008;26:5705-12.